News - Biotie Therapies

Filter

Current filters:

Biotie Therapies

Popular Filters

Biotie invests in Alzheimer’s drug SYN120 as it drops epilepsy pathway

Biotie invests in Alzheimer’s drug SYN120 as it drops epilepsy pathway

11-03-2014

Finland-based Biotie Therapies (Nasdaq OMX: BTH1V), which is focused on neurodegenerative and psychiatric…

BiotechnologyBiotie TherapiesFinancialFinlandHealthcareNeurologicalNRL-1SYN120

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan

31-10-2013

Biotie Therapies says that its partner, Lundbeck has expanded its existing alliance with Otsuka Pharmaceutical…

Asia-PacificBiotechnologyBiotie TherapiesLicensingLundbeckMarkets & MarketingnalmefeneNeurologicalSelincro

Lundbeck launches Selincro in Italy

Lundbeck launches Selincro in Italy

26-09-2013

Danish CNS drug specialist Lundbeck has brought Selincro on the market in Italy.

Biotie TherapiesItalyLundbeckMarkets & MarketingNeurologicalPharmaceuticalSelincro

Biotie completes planned portfolio review

Biotie completes planned portfolio review

24-09-2013

Biotie Therapies has revealed the outcome of its planned portfolio review, following its success earlier…

Biotie TherapiesLicensingLundbeckNeurelisNeurologicalNRL-1PharmaceuticalResearchSelincrotozadenantUCB

Biotie buys option to acquire Neurelis, and opportunity for epilepsy candidate

04-06-2013

Finland-based biotech firm Biotie Therapies (Nasdaq-OMX; BTH1V) says that it has obtained an exclusive…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurelisNeurologicalNRL-1Pharmaceutical

Launch of Biotie/Lundbeck's Selincro will see a paradigm shift in alcohol addiction market

10-05-2013

US and European psychiatrists and US managed care organization (MCO) pharmacy directors surveyed by advisory…

Biotie TherapiesEuropeLundbeckMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSelincro

UCB licenses global rights to tozadenant in Parkinson's disease from Biotie

27-02-2013

Finland-based Biotie Therapies (Nasdaq-OMX: BTH1V) says that UCB (Euronext Brussels; UCB), Belgium's…

Biotie TherapiesLicensingNeurologicalPharmaceuticaltozadenantUCB

Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal

07-09-2012

Danish CNS drug specialist Lundbeck A/S (LUND: DC) said this morning that it has made an investment of…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckMergers & AcquisitionsNeurologicalPharmaceuticalSelincro

Biotie assets available for partnering; update on tozadenant

08-07-2012

Finland-based biotech firm Biotie Therapies' (OMX: BTH1V) retention of SYN120 rights after Roche decided…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckNeurologicalResearchSelincroSYN120tozadenantUCB

Roche returns rights to Biotie Therapies SYN120

27-06-2012

Finland-based Biotie Therapies (OMX: BTH1V) said yesterday that it is retaining global development and…

Biotie TherapiesLicensingNeurologicalPharmaceuticalRocheSYN120

Lundbeck submits Selincro in EU; Novo Nordisk files Degludec in Japan

22-12-2011

Danish CNS drug specialist Lundbeck (LUND: DC) revealed yesterday that it has submitted a marketing authorization…

Asia-PacificBiotie TherapiesDegludecDiabetesEuropeLundbeckNeurologicalNovo NordiskPharmaceuticalRegulationSelincro

UCB pulls out of Biotie partnership on SYN118

25-11-2011

Finland-based Biotie Therapies (Nasdaq-OMX: BTH1V) says that, as it had already expected following disappointing…

Biotie TherapiesLicensingNeurologicalPharmaceuticalUCB

Repligen to buy Novozymes Biopharma Sweden business for $23 upfront; Biotie pulls out of Newron acquisition

28-10-2011

USA-based Repligen (Nasdaq: RGEN) says it has signed a definitive agreement to acquire the business of…

Biotie TherapiesMergers & AcquisitionsNewron PharmaNovozymesPharmaceuticalRepligensafinamide

Benefits of Biotie’s 45 million-euro buy of Newron assessed by Edison Research

16-10-2011

Finland-based Biotie Therapies’ (OMX: BTH1V) proposed c 45 million-euro all-stock merger with Italian…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalResearch

Biotie to buy Newron for 45 million euros, creating a European leader in CNS drug development

27-09-2011

In a second acquisition this year, Finland-based biotech company Biotie Therapies (OMX: BTH1V) has entered…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceutical

Back to top